Affiliation:
1. Center for Human and Environmental Microbiome, School of Public Health, Seoul National University, Seoul, South Korea
2. N-Bio, Seoul National University, Seoul, South Korea
Abstract
ABSTRACT
Metformin is commonly used as the first line of medication for the treatment of metabolic syndromes, such as obesity and type 2 diabetes (T2D). Recently, metformin-induced changes in the gut microbiota have been reported; however, the relationship between metformin treatment and the gut microbiota remains unclear. In this study, the composition of the gut microbiota was investigated using a mouse model of high-fat-diet (HFD)-induced obesity with and without metformin treatment. As expected, metformin treatment improved markers of metabolic disorders, including serum glucose levels, body weight, and total cholesterol levels. Moreover,
Akkermansia muciniphila
(12.44% ± 5.26%) and
Clostridium cocleatum
(0.10% ± 0.09%) abundances increased significantly after metformin treatment of mice on the HFD. The relative abundance of
A. muciniphila
in the fecal microbiota was also found to increase in brain heart infusion (BHI) medium supplemented with metformin
in vitro
. In addition to the changes in the microbiota associated with metformin treatment, when other influences were controlled for, a total of 18 KEGG metabolic pathways (including those for sphingolipid and fatty acid metabolism) were significantly upregulated in the gut microbiota during metformin treatment of mice on an HFD. Our results demonstrate that the gut microbiota and their metabolic pathways are influenced by metformin treatment.
Publisher
American Society for Microbiology
Subject
Ecology,Applied Microbiology and Biotechnology,Food Science,Biotechnology
Cited by
313 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献